What is CBC?
A Guide to Cannabichromene
Cannabichromene, commonly known as CBC, is one of the many naturally occurring cannabinoids found in the cannabis plant. While it is not as widely recognised as THC (tetrahydrocannabinol) or CBD (cannabidiol), CBC is drawing increasing scientific interest for its potential therapeutic properties.
CBC is a non-intoxicating cannabinoid, meaning it does not produce the “high” associated with THC. It was first discovered in 1966 and is considered one of the “big six” cannabinoids studied in cannabis research.
Although CBC is typically found in lower concentrations than THC or CBD, it is thought to contribute to the overall entourage effect — the theory that cannabinoids and terpenes may work better together than in isolation.
Potential Benefits of CBC
Research into CBC is still emerging, but early studies suggest potential roles in:
​
-
Pain and inflammation – Animal studies indicate CBC may interact with pain pathways and reduce inflammation (Turna et al., 2023).
-
Neurological health – Some preclinical studies suggest CBC may support brain function by promoting neurogenesis (DeLong et al., 2021).
-
Mood regulation – CBC has been linked to receptors that influence pain and mood, including TRP channels.
How is CBC Different from Other Cannabinoids?
-
Unlike THC, CBC does not cause intoxication.
-
Unlike CBD, which has been widely researched and is available in prescription products in Australia, CBC is still being studied and is not prescribed as an isolated compound.
-
CBC often works in synergy with THC and CBD, potentially enhancing their effects.
CBC and ECS
Like other cannabinoids, CBC interacts with the body’s endocannabinoid system (ECS), but in unique ways.
​
-
CBC does not strongly bind to CB1 or CB2 receptors, where THC and CBD act.
-
Instead, CBC has been shown to activate TRPA1 channels, which are linked to pain perception and inflammation (De Petrocellis et al., 2011; Romano et al., 2013).
-
There is also evidence that CBC can stimulate TRPV1 receptors — the same receptor targeted by capsaicin (the compound in chilli peppers) — suggesting possible roles in pain and mood regulation (De Petrocellis et al., 2011).
These findings suggest CBC may influence how the body processes pain, inflammation, and mood, without producing intoxication.
CBC may not be as well-known as THC or CBD, but it is an important part of the cannabis plant’s chemical profile. Early studies suggest potential benefits for pain, inflammation, and mood, though more research is needed in humans
Disclaimer: This post is for informational purposes only and does not constitute medical or legal advice. Laws regarding prescription medicines vary by region, and readers should always consult with a qualified healthcare provider before using any prescription medication.
​References: CAMS-22 Survey. (2024). Medical cannabis use in Australia seven years after legalisation. Harm Reduction Journal, 21(1), 15. DeLong, G. T., Wolf, C. E., Poklis, A., & Lichtman, A. H. (2021). Pharmacological evaluation of cannabichromene and its modulation of behavioural effects of Δ9-tetrahydrocannabinol. Frontiers in Pharmacology, 12, 643857. De Petrocellis, L., et al. (2011). Effects of cannabinoids and Cannabis extracts on TRP channels. British Journal of Pharmacology, 163(7), 1479–1494. Romano, B., et al. (2013). Cannabinoid CB2 and TRPA1 receptors mediate the antinociceptive effect of cannabichromene. British Journal of Pharmacology, 169(3), 633–645. Turna, J., Simpson, W., & Van Ameringen, M. (2023). The evolving evidence for cannabinoids in psychiatry. Journal of Psychiatry & Neuroscience, 48(2), E123–E134.